

Date: 08 February 2025

To

The Secretary <b>BSE Limited</b> Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 <b>Scrip Code: 544293</b>	The Secretary <b>The National Stock Exchange of India Limited</b> Exchange Plaza, Plot No. C/1. G Block Bandra -Kurla Complex, Bandra (East) Mumbai- 400 051 <b>Scrip Symbol : SURAKSHA</b>
---	--

Dear Sir / Ma'am,

**Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

**Sub: Press release**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed herewith the press release in relation to the unaudited financial results (both standalone and consolidated) of the Company for quarter and nine months ended 31 December 2024.

Further, details as required to be disclosed as per BSE's Circular No. 20230714-34 dated July 14, 2023, and NSE's Circular No. NSE/CML/2023/57 dated 14 July 2023 are as under:

Date of occurrence of Event/Information: 08 February 2025

Time of occurrence of Event/Information: 6.00 pm

This may please be informed to all the concerned.

For **Suraksha Diagnostic Limited**

\_\_\_\_\_  
**Mamta Jain**

Company Secretary and Compliance Officer


Encl: as above

## Strong Performance in Q3 & 9M FY25

*Impressive 9M FY25 Performance with Total Income growth of 14.4% YoY  
EBITDA Up by 22.4% with margin expansion of 229 bps Y-o-Y to reach 34.8%*

Kolkata, 8<sup>th</sup> February 2025: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter and nine months ended December 31<sup>st</sup>, 2024.

### 9M FY25 Financial Performance Snapshot (Y-o-Y)



### Key Financial Highlights

Particulars (INR Mn)	Q3 FY25	Q3 FY24	Y-o-Y	Q2 FY25	Q-o-Q	9M FY25	9M FY24	Y-o-Y
Total Income	601.12	526.69	14.13%	680.67	-11.69%	1,900.27	1,660.92	14.41%
EBTIDA	188.55	161.63	16.66%	245.07	-23.06%	650.84	531.69	22.41%
EBTIDA Margin (%)	31.68%	31.19%		36.71%		34.80%	32.52%	
PAT	59.85	45.38	31.89%	101.56	-41.07%	238.07	168.05	41.67%
PAT Margin (%)	10.06%	8.76%		15.21%		12.73%	10.28%	

**Highlights:**

**Revenue from Operations:**

- For Q3 FY25, the company reported revenue from operations of INR 595.1 million, reflecting a growth of 14.8% compared to the same quarter last year.
- For the nine months ended FY25, revenue amounted to INR 1,870.0 million, a growth of 14.4% year-on-year.

**EBITDA:**

- EBITDA for Q3 FY25 reached INR 188.6 million, marking a 16.7% increase from Q3 FY24. The EBITDA margin for Q3 FY25 stood at 31.7%, up from 31.2% in the same quarter last year.
- For the nine months ended FY25, EBITDA totaled INR 650.8 million, a growth of 22.4% year-on-year, The EBITDA margin for nine months stood at 34.8%. up from 32.5% in the corresponding period.

**Profit After Tax (PAT):**

- PAT for Q3 FY25 stood at INR 59.9 million, reflecting a growth of 31.9% year-on-year. The PAT margin for Q3 FY25 was 10.1%, compared to 8.8% in the same quarter last year.
- For the nine months ended FY25, PAT reached INR 238.1 million, an increase of 41.7% year-on-year.
- These strong results highlight the company's continued growth, driven by both operational efficiency and strategic execution.

**Commenting on the results Ms Ritu Mittal, Joint Managing Director & CEO said, -**

*We reported strong performance during the third quarter and nine months ended FY25 and remain poised to continue to deliver strong revenue growth and margins over the long term.*

*Given the expectations, our performance was curtailed in current quarter due to external factors such as the doctors' strike, which had a lingering adverse impact on our operations during the quarter. The seasonal weakness during the third quarter reflected in a pull-back in our top-line and EBITDA levels, when comparing on a quarter-on-quarter basis. However, margins were partially supported on a year-over-year basis on the back of efficient cost control measures.*

*We remain steadfast in our focus on internal growth through the addition of new centers as well as exploring inorganic growth opportunities. These focus areas position us well to further strengthen our dominance in the Eastern region of India. We expect to continue to leverage our strong presence to drive a pick-up in the business and margins going forward.*

**About Suraksha Diagnostic Limited:**

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with a presence in the states of West Bengal, Bihar, Assam and Meghalaya.

The company's central reference laboratory is accredited by the College of American Pathologists, while the 3 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 3 advanced diagnostic centers are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Company: Suraksha Diagnostic Limited	Investor Relations: Orient Capital
Email: <a href="mailto:investors@surakshanet.com">investors@surakshanet.com</a>	Name: Mr. Ashish Tendulkar Email: <a href="mailto:ashish.tendulkar@linkintime.co.in">ashish.tendulkar@linkintime.co.in</a> Tel: +91 9820953312
CIN: L85110WB2005PLC102265	Name: Pooja Swami Email: <a href="mailto:pooja.swami@linkintime.co.in">pooja.swami@linkintime.co.in</a> Tel: +91 9860202359
Website: <a href="https://www.surakshanet.com/">https://www.surakshanet.com/</a>	

**Safe Harbor**

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.